IPP Bureau
Zydus receives final approval from the USFDA for Isoproterenol Hydrochloride Injection
By IPP Bureau - April 17, 2023
Isoproterenol hydrochloride injection is indicated to improve hemodynamic status in patients in distributive shock and shock due to reduced cardiac output
CII co-organizes Digital Health Summit 2023 with Health Ministry
By IPP Bureau - April 17, 2023
The Theme of the event was 'Building One Health Together – Improving Health Equity'
G 20: 2nd Health Working Group Meeting discusses global collaboration in research and regional manufacturing for diagnostics
By IPP Bureau - April 17, 2023
The meeting provides recommendations to the G20 and its Member States and international partners on the establishment of a R&D and manufacturing network for diagnostics
Merck acquires Prometheus Biosciences for US$10.8 billion to strengthen immunology pipeline
By IPP Bureau - April 17, 2023
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
Moderna and Merck announce an investigational individualized neoantigen therapy
By IPP Bureau - April 17, 2023
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Fibe partners with Pristyn Care to power affordable quality healthcare across India
By IPP Bureau - April 15, 2023
Affordability is key to providing accessible healthcare for Bharat.
NS Pharma announces FDA clearance to initiate phase II study for an Exon 44 skipping candidate
By IPP Bureau - April 15, 2023
Study efficacy measures will include the expression of dystrophin protein and motor function.
Alpenglow Biosciences and Mayo Clinic collaborate to advance pathology and drug development through 3D spatial biology
By IPP Bureau - April 15, 2023
Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging
Taros Chemicals and Welab Barcelona partner for drug Discovery and development services
By IPP Bureau - April 15, 2023
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Chiesi Farmaceutici completes acquisition of Amryt Pharma
By IPP Bureau - April 15, 2023
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
TransCure bioServices expands their team to lead the way in animal welfare
By IPP Bureau - April 14, 2023
The new team members, Solenn Percelay and Noémie Spinelli, will support the organization’s commitment to excellence in humanized mouse model care and use
Digital Health: An opportunity to increase health equity
By IPP Bureau - April 14, 2023
Clinical Decision Support Systems' huge potential to help ensure that each patient can receive high-quality care; study shows a reduction in diagnostic errors from 24% to 2%
FDA accepts application for Merck’s Keytruda plus chemotherapy as first-line treatment for metastatic gastric
By IPP Bureau - April 14, 2023
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
Advanced library amplification mix delivers superior NGS data quality
By IPP Bureau - April 14, 2023
NGS enables researchers to quickly sequence entire genomes and transcriptomes of organisms.
Over 60% of ambulances violates tyre safety requirements: Survey
By IPP Bureau - April 14, 2023
The survey inspected ambulances operating throughout the city
